Acute Ischemic Stroke Clinical Trial
— SERIC-AISOfficial title:
Safety and Efficacy of Remote Ischemic Conditioning in Patients With Acute Ischemic Stroke
he purpose of this study is to determine the efficacy and safety of remote ischemic conditioning for acute ischemic stroke.
Status | Not yet recruiting |
Enrollment | 912 |
Est. completion date | September 20, 2026 |
Est. primary completion date | September 20, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: - 1)Age=18 years, < 80 years, regardless of sex; - 2)Patients with clinically definite diagnosis of acute ischemic stroke and able to commence RIC treatment within 12 hours of stroke onset - 3)Baseline NIHSS score>5, and=25 ; - 4)GCS score =8; - 5)Signed and dated informed consent is obtained Exclusion Criteria: - 1) Patients with suspected posterior circulation infarction; - 2) Patients who undergo thrombolytic therapy or endovascular treatment; - 3) mRS=2 score before the onset of the disease; - 4) Double upper limbs or lower limbs paralysis was found in this case; - 5)Active bleeding of organs within 6 months of admission or current, including cerebral hemorrhage, subarachnoid hemorrhage, gastrointestinal hemorrhage, fundus hemorrhage and so on; - 6) Other intracranial lesions, such as cerebrovascular malformation cerebral venous diseases, tumor and other diseases involving the brain; - 7) Treated blood pressure =90mmHg/60mmHg or=180mmHg/100mmHg; - 8) Severe organ dysfunction or failure; - 9) Persons suffering from severe hematological diseases or severe coagulation disorder dysfunction; - 10) Those who had a history of severe trauma or had major surgery within 6 months prior to admission; - 11) The patients who had the contraindication of remote ischemic conditioning treatment, such as severe soft tissue injury, fracture or vascular injury in the upper limb;Acute or subacute venous thrombosis, arterial occlusive disease, subclavian steal syndrome, etc; - 12) Pregnant or lactating women; - 13) Previous remote ischemic conditioning therapy or similar treatment; - 14) Patients with a life expectancy of less than 3 months or patients unable to complete the study for other reasons; - 15) Severe hepatic and renal dysfunction - 16) Unwilling to be followed up or treated for poor compliance; - 17) He/She is participating in other clinical research or has participated in other clinical research or has participated in this study within 3 months prior to admission; - 18) Other conditions that the researchers think are not suitable for the group. |
Country | Name | City | State |
---|---|---|---|
China | First Hospital of Jilin University | Changchun | Jilin |
Lead Sponsor | Collaborator |
---|---|
Yi Yang |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of patients with Modified Rankin Scale (mRS) Score 0-2 | The primary outcome measure of efficacy is the modified Rankin Scale (mRS) dichotomized to define good functional outcome as mRS 0-2 at 90 days.score, dichotomized to define good functional outcome as mRS 0-2 at 90 days. | 3 months | |
Secondary | NIHSS Score at end of 7th day of treatment | NIHSS Score at end of 7th day of treatment | 7 days | |
Secondary | mRS Score at end of 7th day of treatment | mRS Score at end of 7th day of treatment | 7 days | |
Secondary | Barthel Index at end of 7th day of treatment | Barthel Index at end of 7th day of treatment | 7 days | |
Secondary | Changes of hematological indicators | The changes of hematological indicators (inflammatory cytokine,et al.) between the first 48h and end of 7th day of treatment. | 48h; 7days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06113848 -
Adjunctive Use of Intra-Arterial TNK and Albumin Following Thrombectomy
|
Phase 3 | |
Completed |
NCT04069546 -
The Efficacy of Remote Ischemic Conditioning on Stroke-induced Immunodeficiency
|
N/A | |
Active, not recruiting |
NCT05700097 -
Dengzhanxixin Injection for Acute Ischemic Stroke Receiving Reperfusion Therapy
|
Phase 2 | |
Recruiting |
NCT06058130 -
Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis
|
N/A | |
Recruiting |
NCT04415164 -
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
|
Phase 4 | |
Recruiting |
NCT05363397 -
Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke
|
Phase 2 | |
Completed |
NCT05429658 -
Single Arm Trial to Evaluate the Safety and Effectiveness of the Route 92 Medical Reperfusion System
|
N/A | |
Recruiting |
NCT05390580 -
Neuromodulation Using Vagus Nerve Stimulation Following Ischemic Stroke as Therapeutic Adjunct
|
N/A | |
Enrolling by invitation |
NCT05515393 -
A Study of XY03-EA Tablets in the Treatment of Acute Ischemic Stroke
|
Phase 2 | |
Active, not recruiting |
NCT05070260 -
ACTISAVE: ACuTe Ischemic Stroke Study Evaluating Glenzocimab Used as Add-on Therapy Versus placEbo
|
Phase 2/Phase 3 | |
Terminated |
NCT05547412 -
Validation of Velocity Curvature Index as a Diagnostic Biomarker Tool for Assessment of Large Vessel Stroke
|
||
Completed |
NCT03366818 -
New Stent Retriever, VERSI System for AIS
|
N/A | |
Not yet recruiting |
NCT05293080 -
Early Treatment of Atrial Fibrillation for Stroke Prevention Trial in Acute STROKE
|
Phase 3 | |
Not yet recruiting |
NCT06040476 -
Human Umbilical Cord Blood Infusion in Patients With Acute Ischemic Stroke (AIS)
|
Phase 2 | |
Completed |
NCT02223273 -
Brazilian Intervention to Increase Evidence Usage in Practice - Stroke (BRIDGE-Stroke)
|
N/A | |
Completed |
NCT02586233 -
Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke
|
Phase 1/Phase 2 | |
Terminated |
NCT01694381 -
Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor
|
Early Phase 1 | |
Not yet recruiting |
NCT01594190 -
Physical Activity Immediately After Acute Cerebral Ischemia
|
N/A | |
Completed |
NCT01120301 -
Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)
|
Phase 3 | |
Completed |
NCT00963989 -
Imaging Guided Patient Selection for Interventional Revascularization Therapy
|
N/A |